Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I thought he said HOT IND in the next several weeks. Not sure he said this month but I’ll go back and listen
I just love that the pps just continues to get hammered the same posters always have an excuse or some goofy theory. Why can’t it ever be that the company( also the BOD) to date have done a piss poor job and we need a miracle right now to dig us back out
Do people really believe the BS he post about his buddy that works for a large investment firm. Same buddy that told him Dan had bought or sold shares(sure) and had given him documents to prove it but then oops I can’t share them with anyone, lol. Ok! Sure!
Yes I started reading about it but I wonder what the MC cut off is and it seems like it goes off what the company did the previous yea. Anyway either way you look at it. It’s not pretty were we sit right now. Never would have thought we be this low with no negative trials to report to date
I thought I read that the Russel rebalancing was happening because they fell below $2. Is this true or not? If so then the insiders were buying most likely to try to get the price back over $2. If not then the buys sure do seem timed or like you said. They would have had to know they could buy cheaper
I would take a buyout at $10 first thing Monday. This BOD can’t be trusted!!!
WOW just wow! I guess the buying the BOD did to try to get this moving the other way didn’t work. Just unbelievable how this man has remained as head of the BOD for this many years. He should be taken out back......
Catt, if it’s the best thing in Prostate trials right now. Then why didn’t both companies announce a collaboration to move into a larger phase 2/3 trial. Where Big momma Merck picked up the bill. Come on people, holy cow. I guess I just don’t get it
Is the PSA data better then what’s already available to date?? Doesn’t seem like and if it was. Merck would have made a move already. So l believe and I could be wrong that it will be just a waste of time. I wish and we all wish the data would have been out of this world but it wasn’t. Just like I said going into ASCO. It was just going to be okay and now they aren’t really sure what to do with it. Also our CSO talks about one of the IND’s for HOT will be for prostate cancer. Why? Because what we have right now isn’t good enough. It’s good but not great
Ziopharm Oncology, Inc. (ZIOP) today announced the U.S. Food and Drug Administration (FDA) placed on clinical hold a Phase 1 trial to evaluate CD19-specific CAR-T therapies manufactured under point-of-care and requested additional information in support of the investigational new drug (IND) application for the trial
Even if the deal is in the works I don’t think they can buy like they did today. Hopefully they are buying for the same reason I bought today. With the first patient now dosed in NEO trial. It won’t be long before they start to see some early results and if they think they are going to knock it out of the park. I can’t see how Amgen doesn’t buy the HOT program in the next 6 months
My apologies in advance. I only read the approval very quickly but in the KEYNOTE-158. We are definitely sure that the patients were heavily pretreated. I thought I read they only had to have one prior treatment and didn’t they also get to pick all patients that were PD1 positive. I know in the GOG-265 most patients had probably 2-3 prior lines of treatment and we didn’t get to hand pick anything. Am I wrong, thanks
I took a little bite at $1.69. Couldn’t help myself. Not a big fan of what’s going on with AXAL but hoping HOT brings in some big money
Chris Duke gone!!! Kenny boy is cleaning house
Hd, trust me when I tell you I sure hope so because I believe this is this company’s last chance to get it right. Also remember Tony L just a few months ago came up with a plan that went no where.
Yesterday was just more fluff and damage control. SHOW ME THE MONEY!!!!! DAN O GAVE AWAY NEO FOR PEANUTS but at least it seems like we might have a CEO that’s ready to cut cost
“They will easily get a partnership if the EMA approves.”. This is exactly the garbage I’m talking about!!
1st. They haven’t landed a partner yet, why?
2nd. Your key word “ IF” and that’s a big if
3rd. They are telling you they are going to wind down our phase 3 trial if they can’t find a partner and what do think they have been doing all this time.
4th. Most of you know that phase 3 would have helped get us approval from EU
Wow people are just unbelievable. The company is talking about dropping our most advanced trial and people are taking it as good news. Holy crap the world we live in. I’m excited that they are cutting cost and focusing on NEO & HOT but rather see them give AXAL away for free with large future royalties then just shut it down like they have done with everything else so far
Still own everyone of my shares but sorry you can’t handle a real opinion that’s not all rainbows with pots of gold at the end. Here is this better. What this news means is that a partner is going to step in next week and give us 200 million up front to take over AXAL program and speed along the EU process. Oh and also pays us 40% royalties on all future sales. Hope that makes you feel better, wake up
EU is most likely done I believe because if approved it most likely would have been a conditional approval based on more data from phase 3. So unless they find a partner in a hurry. I don’t think it looks good but I’m also wondering if there is more going on with the hold then they are telling us
Wow what a mess and all the wasted money that went towards AXAL. If they can’t find a partner wind down the phase 3 study. Well there goes the EU approval as well and once again even more wasted money and time. This is just ridiculous and disgusting
It’s a good possibility that the hold will never be lifted and the trial will remain suspended because it’s Astra’s PD-L1 that caused the death but that would mean more holds on over 200 other trials they are running and we no that isn’t going to happen or maybe they can’t find the exact cause.
18.4 months is a good OS rate but the questions is what percentage of patients make it to that 18.4 months.
Clock is ticking!!!!! I said last year that if things don’t change by mid 2018. It could be game over for this baby bio. Here’s to hoping that NEO trial gets started very soon(I think this is a big milestone). Can only pray that the company and new CEO have something worth talking about this coming week. To many many investors on this board think that early approval for AXAL in EU is a done deal, it’s not going to be that easy. We need something to happen very soon or we will find ourselves back to the days of ugly financing deals and R/S. It will be interesting to see if they mention how many employees are working for Advaxis like they have in the past. High hopes to a strong week!!!!!
Yes we do! Just not sure where it’s coming from. Unless they make a deal for ADXS-HOT. We are still waiting for the start of NEO. Which I hope happens this month. Really don’t understand the delay but I think Advaxis wasn’t ready on the manufacturing side on their end.
Sounds like the data being used in ADXS- PSA trial was from March 2018. They said they would like to see how these patients are doing in 6 more months. If the patients continue to do well and data improves. We most likely won’t get another update until late 2018
ClinicalTrials.gov Identifier: NCT02787005. Is this trial with Merck’s Keyturda comparable to our combo trial? If so won’t they want to see how Keyturda does on its own before giving away millions on a combo trial that right now just seems to be okay but not great. Just asking because it might give us a better idea what to expect going forward.
There isn’t to much further they can crash. Phase 3 company and we sit around a 100 million market cap
This must be part of the delay. Also sounds like they are have problems getting it done in house
Cash out!!!!!!
Yes I would say the clinical Hold has now become a bit ridiculous but I guess anything to keep this small bio down
In years past I believe they always came out much later in the day. Like 8pm
It will be interesting to see if this run up is connected to ASCO abstract release. Which would mean the data could actually be interesting instead of just boring like I had thought we were going to get. Well at least I hope so! That would be a game changer in my book
End of day news!!! $1.50 offering on 15 million shares, lol. Just kidding but like others are saying. We might get PR next week first NEO patient dosed. Still would like to see the HOLD resolved ASAP
I wish he would just keep is fat mouth shut
Nice buy!! I’m thinking of adding(told myself I would never add more, lol). Love the pps right now but want to wait until we get info on the hold. I hope news of the hold being lifted doesn’t change the pps right away but I think it should be any day now that we are at the 2 month mark
For all of you that think this HOLD is no big deal. They are making it very clear even in the corporate presentation
“ We do not ANTICIPATE that this hold will impact our EU MAA for axalimogene filolisbac.
Enrollment and dosing in all other Advaxis clinical programs are unaffected at this TIME”
The hold needs to be cleared up and lifted so we can move on and not worry
The hold needs to be lifted. Otherwise there is still the chance they could extend it to other ongoing trials. That’s my biggest concern. I could care less if they stop that specific trial all together but the Hold needs to be put to rest. We are also a company now running with no CFO!!! I’m sure that looks real good to any interested investors. What a mess!!!
We need news that the hold has been lifted or resolved. Two months now this is getting a bit ridiculous but just like our last Hold was dragged out as long as possible. Someone at Advaxis has pissed off someone at the FDA.
Dan O continues his great deal making skills as you can see from the PR this morning
Followed by Wednesday, Thursday and Friday